ReviewBiomolecules2026
HDAC3 as an Immunometabolic Rheostat: Molecular Mechanisms of Deacylation Plasticity, Lactylation Dynamics, and Spatiotemporal Regulation.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Histone deacetylase 3 (HDAC3) is a key node linking immunometabolism, chromatin regulation, and inflammatory transcriptional programs. Rather than functioning simply as a nuclear deacetylase, HDAC3 output is jointly shaped by corepressor-complex assembly, metabolic and acyl-substrate availability, and compartment-specific substrate access. The identification of lysine lactylation and the discovery of delactylase activity in HDAC1-3 have expanded the mechanistic boundaries of HDAC3, repositioning it from a canonical deacetylase toward an emerging regulatory node involved in the dynamic control of multiple acyl modifications. This review examines the complex-dependent activation of HDAC3, its regulation of nuclear inflammatory transcriptional thresholds, the proposed redistribution of its catalytic output across acetylated and lactylated substrates under increased lactate load, and candidate extra-nuclear non-histone acylation networks involving inflammatory signaling proteins and metabolic enzymes. Current evidence supports bona fide delactylase activity of HDAC3 in biochemical systems; however, whether HDAC3 directly delactylates specific cytoplasmic substrates in physiologically relevant settings requires further validation at the compartmental, site-specific, and functional levels. Viewing HDAC3 as an immunometabolic rheostat helps explain its context-dependent functions in inflammatory homeostasis, acute activation, and metabolic stress, and provides a conceptual basis for developing selective, complex-state-sensitive, and function-stratified HDAC3-targeted strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.